Benchmarking Boltz-2 for Screening of Therapeutic Antibody-Antigen Interactions (opens in new tab)
Protein structure prediction models (such as AlphaFold, Chai, Boltz) have transformed structural biology and are increasingly explored for drug discovery; however, their utility for large-scale screening of antibody-antigen (AB-AG) interactions remains unclear, particularly for distinguishing true binding from non-binding pairs at scale. To our knowledge, there has not been an exhaustive exploration of Boltz-2 inference settings on this high impact problem, and in this paper we set out to des...
Read the original article